Robert Hallowell
Overview
Explore the profile of Robert Hallowell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
72
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, et al.
Arthritis Rheumatol
. 2024 Jul;
76(8):1182-1200.
PMID: 38978310
Objective: We provide evidence-based recommendations regarding the treatment of interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases (SARDs). Methods: We developed clinically relevant population, intervention, comparator, and...
2.
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, et al.
Arthritis Care Res (Hoboken)
. 2024 Jul;
76(8):1051-1069.
PMID: 38973731
Objective: We provide evidence-based recommendations regarding the treatment of interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases (SARDs). Methods: We developed clinically relevant population, intervention, comparator, and...
3.
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, et al.
Arthritis Care Res (Hoboken)
. 2024 Jul;
76(8):1070-1082.
PMID: 38973729
Objective: We provide evidence-based recommendations regarding screening for interstitial lung disease (ILD) and the monitoring for ILD progression in people with systemic autoimmune rheumatic diseases (SARDs), specifically rheumatoid arthritis, systemic...
4.
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, et al.
Arthritis Rheumatol
. 2024 Jul;
76(8):1201-1213.
PMID: 38973714
Objective: We provide evidence-based recommendations regarding screening for interstitial lung disease (ILD) and the monitoring for ILD progression in people with systemic autoimmune rheumatic diseases (SARDs), specifically rheumatoid arthritis, systemic...
5.
Dimala C, Patel U, Lloyd B, Donato A, Kimmel W, Hallowell R, et al.
Case Rep Pulmonol
. 2021 Nov;
2021:9343491.
PMID: 34820143
Fewer than ten reported cases of cryptogenic organizing pneumonia (COP) have been managed with intravenous immunoglobulins (IVIg). We report a case of a 72-year-old man who presented with a worsening...
6.
Soskis A, Hallowell R
Respiration
. 2021 May;
100(9):923-932.
PMID: 33951665
Interstitial lung disease (ILD) is a cause of substantial morbidity and mortality amongst autoimmune diseases, including myositis. Despite first-line therapy with immunosuppression, many inflammatory ILDs advance to a fibrotic stage....
7.
Rahaghi F, Belperio J, FitzGerald J, Gulati M, Hallowell R, Highland K, et al.
Clin Med Insights Circ Respir Pulm Med
. 2021 Apr;
15:11795484211006050.
PMID: 33854398
Purpose: Nintedanib is an approved treatment for idiopathic pulmonary fibrosis (IPF), which slows disease progression. Management of patients with IPF receiving nintedanib can be complicated by tolerability issues, comorbidities, and...
8.
Richeldi L, Varone F, Bergna M, De Andrade J, Falk J, Hallowell R, et al.
Eur Respir Rev
. 2018 Dec;
27(150).
PMID: 30578333
A proportion of patients with interstitial lung diseases (ILDs) are at risk of developing a progressive-fibrosing phenotype, which is associated with a deterioration in lung function and early mortality. In...
9.
Hamblin M, Eberlein M, Black K, Hallowell R, Collins S, Chan-Li Y, et al.
Int J Biomed Sci
. 2014 Oct;
10(3):146-57.
PMID: 25324695
Background: Lovastatin has a unique ability to bind Leukocyte Function Antigen-1 (LFA-1), an integrin necessary for the full expression of inflammatory cytokines induced by the low molecular weight form of...